Mereo BioPharma Group plc — Q1 2024 Form 10-Q Summary
Business context and reporting period
Mereo is a U.K.-based biopharmaceutical company developing rare-disease therapeutics. Its principal candidates are setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. The unaudited report covers the three months ended March 31, 2024, with comparison to March 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.0 million | $5.3 million |
| General and administrative expense | $5.9 million | $6.5 million |
| Loss from operations | $9.9 million | $11.4 million |
| Net loss | $9.0 million | $12.1 million |
| Net loss per share | $0.01 | $0.02 |
| Net cash used in operating activities | $8.0 million | $9.2 million |
| Cash and cash equivalents at period-end | $48.7 million | $59.8 million |
Gross and operating margins are not meaningful because the company generated no revenue. Total comprehensive loss was $9.7 million, including a $0.8 million foreign-currency translation loss. Accumulated deficit was $428.6 million at March 31, 2024.
Total assets were $55.9 million and shareholders’ equity was $42.8 million. Convertible loan notes totaled $4.6 million, classified as current and due in February 2025. The company also reported $0.9 million of non-current warrant liabilities and $1.4 million of operating lease liabilities.
Material changes versus the prior comparable period
- Net loss improved by $3.1 million, or 26%, primarily because of lower R&D and G&A expenses, lower interest expense, and a favorable foreign-exchange result.
- R&D expense declined 25%. Etigilimab costs decreased by $1.8 million as its Phase 1b/2 study wound down, partly offset by higher spending on setrusumab and alvelestat.
- G&A expense declined 8%, including a $1.7 million reimbursement from the company’s depositary for ADR-related expenses and higher employee-related and professional costs.
- Interest expense fell to $0.3 million from $0.8 million because the private-placement loan notes were converted or redeemed in 2023. Interest income increased to $0.6 million from $0.3 million because of higher deposit rates.
- Fair-value changes in financial instruments shifted from a $0.5 million gain to a $0.4 million loss, principally reflecting the higher ADS price and resulting warrant valuation.
- Cash declined by approximately $8.8 million during the quarter, from $57.4 million at December 31, 2023 to $48.7 million at March 31, 2024. The company used $8.0 million in operating activities and $0.7 million for intangible assets, with an additional foreign-exchange effect.
Guidance, outlook, risks and unusual items
- Management expects cash and cash equivalents at March 31, 2024 to fund operations and capital expenditures for at least twelve months from the filing date. Its current business plan forecasts cash resources extending into 2026, but management states that additional external funding will be needed to complete development plans and potentially commercialize products.
- The company expects continuing operating losses and has no approved products or product-sales revenue. Future financing may include equity, debt, collaborations, licensing transactions or other non-dilutive sources, potentially causing dilution or requiring the company to relinquish rights.
- The remaining convertible loan note matures in February 2025. Management currently assumes it will be converted or refinanced with new debt or equity; repayment could materially affect liquidity if those alternatives are unavailable.
- Manufacturing commitments to contract manufacturers totaled $3.1 million at March 31, 2024. Additional potential milestone, royalty and other payments under the Novartis and AstraZeneca agreements remain uncertain; AstraZeneca development and regulatory milestones could total up to $115.5 million, plus potential equity issuances and royalties.
- On April 30, 2024, partner Ultragenyx announced completion of enrollment in the Phase 3 Orbit and Cosmic studies of setrusumab, with 158 and 66 patients enrolled, respectively.
- On April 23, 2024, the contingent value rights agreement expired with no further amounts payable. The gross potential payments had been approximately $80.0 million, but the recorded liability was zero before expiration.
- On April 15, 2024, the cooperation agreement with Rubric Capital was extended through immediately after the 2025 annual shareholder meeting.
- The company reported no material litigation, no material changes to previously disclosed risk factors, and effective disclosure controls as of March 31, 2024.
Important facts for investors to verify
- Whether the projected cash runway into 2026 remains achievable given clinical, manufacturing and corporate spending.
- The terms and timing of any conversion, refinancing or repayment of the $4.6 million Novartis convertible loan note due in February 2025.
- Progress, results and regulatory implications of the fully enrolled setrusumab Phase 3 studies.
- Funding requirements and development milestones for alvelestat, including the timing and cost of any Phase 3 study.
- Potential dilution from future equity financing, employee awards, convertible debt and warrants.
- The timing, probability and amount of contingent milestone, royalty and licensing payments under the Novartis and AstraZeneca agreements.
- The effect of non-recurring reimbursements and insurance proceeds on Q1 cash-flow comparability.